Share

Françoise Meunier, EORTC Director General, discusses issues facing cancer survivors

Prof Françoise Meunier, EORTC Director General, talked to eCancertv during the ESMO 2014 Congress about her recent article in the Financial Times on cancer and financial impact on cancer survivors.

Watch here the video of the interview

Early diagnosis, innovative drugs and integrated therapeutic strategies combining chemotherapy, surgery and radiotherapy have resulted in dramatic increases in cancer survival rates. In fact, EORTC trials have led to long term survival and cure for children with leukaemia and patients with Hodgkin’s lymphoma or testicular and breast cancers.

This success is good news, but it brings with a host of unanticipated issues facing cancer survivors, who are frequently excluded from insurance, mortgages and jobs.

The EORTC is active in addressing these issues. The 1st EORTC Cancer Survivorship Summit facilitated interactions between clinicians, researchers, social workers, patients, insurers, bankers and policy makers, and addressed second malignancies, cardiovascular disease, cognitive dysfunction, infertility/sexuality and psycho-social problems following cancer treatment. In light of the success of the first summit, a 2nd EORTC Cancer Survivorship Summit will be held 31 March – 01 April 2016 in Brussels, and in Spring 2015 the EORTC will organize a special cancer and employment forum for European employers, patients, and politicians.

John Bean, PhD
EORTC, Medical Science Writer

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023